Medications can trigger suicidal thoughts through several biological pathways, depending on the drug. The risk is highest in the first few weeks of treatment, particularly the first nine days, before the brain has fully adjusted to the chemical changes the medication introduces. This isn’t limited to antidepressants. Seizure medications, acne treatments, asthma drugs, and others carry similar risks for some people.
Understanding why this happens requires looking at what these drugs do inside the brain and who is most vulnerable.
The Early Treatment Paradox
The most well-studied example involves antidepressants, particularly SSRIs (selective serotonin reuptake inhibitors like Prozac, Zoloft, and Lexapro). These drugs block the recycling of serotonin in the brain, making more of it available between nerve cells. But the brain doesn’t respond to this change the way you might expect.
In the first days and weeks, the brain detects the extra serotonin and compensates by dialing down its own serotonin-producing activity. The result is a temporary stalemate: the drug is pushing serotonin levels up, but the brain’s feedback mechanisms are pushing them back down. Net serotonin function doesn’t actually improve during this early phase. It takes several weeks of continuous treatment for the brain’s feedback systems to adapt and allow serotonin signaling to genuinely increase. This mismatch between what the drug is doing and what the brain is doing creates a window of vulnerability.
During this same window, some people experience a boost in physical energy and motivation before their mood improves. A person who was too exhausted by depression to act on dark thoughts may suddenly have the energy to do so, while still feeling hopeless. A study published in JAMA found the risk of suicidal behavior was highest in the first month of antidepressant treatment, and particularly in the first nine days.
Akathisia: The Side Effect That Mimics Crisis
One of the most dangerous and underrecognized contributors is akathisia, an intense inner restlessness that some medications produce. It feels like a crawling, unbearable need to move, paired with severe agitation and distress. People describe it as feeling like they want to jump out of their own skin.
Akathisia is not a worsening of depression. It’s a direct side effect of certain drugs, and it can occur even in people with no prior mental health conditions. Healthy volunteers in clinical drug trials have experienced severe akathisia. The agitation it produces can be so overwhelming that it drives suicidal thoughts or behavior in someone who had none before starting the medication. SSRIs are one class of drugs known to cause it, but antipsychotics and anti-nausea medications can trigger it as well.
Because akathisia looks like worsening anxiety or depression from the outside, it’s frequently misidentified. Recognizing it matters because the appropriate response is usually to adjust or stop the medication, not increase the dose.
Which Medications Carry Warnings
The FDA’s strongest safety label, the black box warning, applies to all antidepressant drugs regardless of class. This includes SSRIs, older tricyclic antidepressants, and newer medications like duloxetine and bupropion. The warning specifically covers patients under 25, the age group where the risk signal is clearest.
Seizure medications also carry a class-wide warning. In 2008, the FDA reviewed 199 clinical trials covering 11 different antiepileptic drugs and nearly 44,000 participants. Patients taking these medications had roughly three times the rate of suicidal behavior compared to those on placebo (about 133 per 100,000 versus 56 per 100,000). These drugs are prescribed not only for epilepsy but also for bipolar disorder, nerve pain, and migraines, so the affected population is large.
Montelukast, an asthma and allergy medication widely prescribed to children, has been linked to depression, sleep disturbances, and suicidal thoughts. Research has shown that montelukast interferes with the brain’s detoxification system and disrupts multiple neurotransmitter pathways, including those that regulate the body’s stress response. Children appear more susceptible, likely because their brains are still developing.
Isotretinoin (Accutane)
The acne medication isotretinoin has long been associated with mood changes. A large meta-analysis of 25 studies covering more than 1.6 million participants found that the one-year risk of suicidal ideation among users was less than 0.5%, and the risk of depression was about 3.8%. Interestingly, the same analysis found that isotretinoin users were actually less likely than nonusers to attempt suicide two to four years after treatment, suggesting the relationship is more complicated than a simple cause-and-effect.
Smoking Cessation Drugs
Varenicline (Chantix) and bupropion (Zyban) once carried black box warnings for neuropsychiatric side effects. However, a large clinical trial called EAGLES, which enrolled thousands of participants with and without psychiatric histories, found no significant increase in neuropsychiatric adverse events from either drug compared to a nicotine patch or placebo. Among participants without psychiatric disorders, the varenicline group actually reported fewer moderate-to-severe neuropsychiatric events (1.3%) than the placebo group (2.4%). The FDA subsequently removed the black box warning from these medications.
Why Some People Are More Vulnerable
Your genes play a significant role in how you process medications. Many antidepressants are broken down in the liver by an enzyme called CYP2D6, and the gene controlling this enzyme varies widely across the population. About 5 to 10 percent of people of European descent are “poor metabolizers,” meaning their version of this enzyme works slowly. In a pilot study of patients experiencing adverse effects from antidepressants, 29% turned out to be poor metabolizers, a rate four times higher than expected in the general population.
If you metabolize a drug slowly, it builds up to higher levels in your blood than your doctor intended. This effectively means you’re getting a stronger dose than prescribed, which increases the likelihood of side effects including agitation, akathisia, and mood disturbances. Pharmacogenetic testing, a simple cheek swab, can identify these variations before treatment begins, though it’s not yet a routine part of prescribing.
Age Makes a Difference
The risk of medication-induced suicidal thoughts is not evenly distributed across age groups. The FDA’s black box warning applies specifically to children, adolescents, and young adults up to age 25. The developing brain appears to respond differently to serotonin changes than the mature brain, though the exact reasons remain unclear. In adults over 25, antidepressants generally show a neutral or protective effect against suicidal behavior, and in older adults, the protective effect becomes more pronounced.
This creates a clinical tension: the age group most likely to experience medication-induced suicidal thoughts overlaps heavily with the age group most likely to have untreated depression. The risk of not treating depression, which itself carries a substantial suicide risk, has to be weighed against the smaller but real risk of the treatment itself.
High-Risk Windows
Three periods carry elevated risk when it comes to medication and suicidal thoughts:
- Starting treatment: The first one to four weeks, with the highest risk concentrated in the first nine days. This is when the brain is adjusting to the new chemical environment and side effects like akathisia are most likely to emerge.
- Dose changes: Increasing or decreasing the dose creates a new adjustment period, similar to starting treatment.
- Discontinuation: Stopping a medication, especially abruptly, can destabilize brain chemistry. However, at least one study found the evidence for discontinuation-related suicidality was weaker than for initiation-related risk.
Current guidelines recommend close monitoring during all three of these windows. This typically means more frequent check-ins with a prescriber in the first weeks of treatment, with family members or close contacts also watching for sudden changes in mood, agitation, or behavior that seem out of character. The warning signs to watch for are not necessarily sadness or withdrawal. Increased irritability, restlessness, impulsivity, or insomnia can all signal a problematic reaction to medication.